Pulmonary arterial hypertension with Pegasys
Pulmonary arterial hypertension has been added as a adverse event with unknown frequency in the summary of product characteristics for Pegasys (peginterferon alfa-2a; Roche). It states that cases of pulmonary arterial hypertension have been reported in patients with risk factors such as portal hypertension, HIV infection and cirrhosis.
Citation: The Pharmaceutical Journal URI: 20069395
Recommended from Pharmaceutical Press
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com